Rocket Pharmaceuticals, Inc. (RCKT) — Analyst outlook / Analyst consensus target is. Based on 19 analyst ratings, the consensus is bullish — 13 Buy, 4 Hold, 2 Sell.
The consensus price target is $5.00, representing an upside of 28.9% from the current price $3.88.
Analysts estimate Earnings Per Share (EPS) of $-2.75 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.73 vs est $-2.75 (beat +0.8%). 2025: actual $-2.01 vs est $-2.05 (beat +2.1%). Analyst accuracy: 99%.
RCKT Stock — 12-Month Price Forecast
$5.00
▲ +28.87% Upside
Average Price Target
Based on 19 Wall Street analysts offering 12-month price targets for Rocket Pharmaceuticals, Inc., the price target is $5.00.
The average price target represents a +28.87% change from the last price of $3.88.
RCKT Analyst Ratings
Buy
Based on 19 analysts giving stock ratings to Rocket Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — RCKT
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.73
vs Est –$2.75
▲ 0.8% off
2025
Actual –$2.01
vs Est –$2.05
▲ 2.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — RCKT
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
